SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Liquidia Technologies and GlaxoSmithKline Advance Existing Collaboration; GlaxoSmithKline Exercises Option for Inhaled Therapeutics
News | 09. 30. 2015
Liquidia Technologies
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2015 -- Liquidia Technologies today announced that GlaxoSmithKline (GSK) has exercised its option under a Collaboration and Option Agreement signed in 2012 to exclusively license the right to research, develop, and commercialize inhaled therapeutics derived from the company's proprietary PRINT® technology. Through this collaboration, Liquidia and GSK will continue to work together with the goal of advancing inhaled therapeutics into clinical studies.
